Amendment No. 3 to Clinical and Commercial Supply Agreement Viral Vector ProductClinical and Commercial Supply Agreement • February 23rd, 2021 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3 to the Clinical and Commercial Supply Agreement-Viral Vector Product (the “Amendment”) is made effective January 1, 2021, (“Amendment Effective Date”) by and between bluebird bio (Switzerland) GmbH (“Company”), and SAFC Carlsbad, Inc., a California corporation (“SAFC”). Company and SAFC may hereinafter be referred to as a Party or as the Parties. Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.
